Europe Infectious Disease Diagnostics Market

Europe Infectious Disease Diagnostics Market Size

The size of the Europe infectious disease diagnostics market was valued at USD 5.81 billion in 2025. This market is expected to grow at a CAGR of 7.34% from 2026 to 2034, reaching a value of USD 10.99 billion by 2034, up from USD 6.24 billion in 2026.

The Europe Infectious Disease Diagnostics Market comprises a sophisticated ecosystem of laboratory and point-of-care technologies designed to detect, identify, and characterize pathogenic microorganisms that cause communicable illnesses across human populations. These diagnostics serve as the frontline defense in clinical management, public health surveillance, and the containment of outbreaks. According to the European Centre for Disease Prevention and Control, millions of notifiable infectious disease cases are reported annually across the European Union, with influenza, respiratory syncytial virus, and foodborne pathogens consistently ranking among the most prevalent. As per the World Health Organization Regional Office for Europe, antimicrobial resistance contributes to an estimated 133,000 deaths annually in the region, making rapid diagnostics essential for stewardship. According to the European Environment Agency, warming temperatures have expanded the habitat range of vector‑borne diseases such as West Nile virus and tick‑borne encephalitis into previously unaffected northern latitudes. In response, the EU’s 2022 Action Plan on Antimicrobial Resistance and the reinforced Health Union framework have prioritized diagnostic readiness as a pillar of health security. This convergence of epidemiological urgency, policy reinforcement, and technological advancement positions infectious disease diagnostics not as a peripheral tool but as a strategic infrastructure component in Europe’s evolving public health architecture.

MARKET DRIVERS

Reinforced EU Health Security Frameworks Elevate Diagnostic Preparedness

The institutionalization of diagnostic capacity within Europe’s restructured health security apparatus has created sustained demand for rapid, accurate, and deployable testing solutions, which is majorly driving the European influenza disease diagnostics market growth. Following the pandemic, the European Commission established the European Health Emergency Preparedness and Response Authority, which allocates dedicated funding for diagnostic stockpiling and laboratory network strengthening. According to the European Centre for Disease Prevention and Control, more than 1,200 laboratories across 30 countries participate in the EU Pathogen Genomics Initiative, which is enabling real-time genomic surveillance of emerging threats. National responses reflect this integration. As per Germany’s Robert Koch Institute, the national reference laboratory network includes dozens of high containment facilities, supporting rapid identification of novel pathogens. Similarly, France’s National Public Health Agency maintains a permanent inventory of rapid antigen tests and molecular kits for immediate deployment. These structural investments transform diagnostics from reactive tools into standing components of national resilience. The EU’s Joint Procurement Agreement for medical countermeasures now includes diagnostics as a core category, ensuring coordinated procurement and reducing fragmentation. This systemic embedding ensures consistent funding cycles, technology refreshes, and training, making diagnostic readiness a non-discretionary public health function.

Rising Antimicrobial Resistance Drives Demand for Pathogen-Specific Testing

The escalating crisis of antimicrobial resistance in Europe has intensified clinical reliance on precise diagnostics to guide targeted therapy and avoid empirical prescribing, which is further contributing to the influenza disease diagnostics market expansion in Europe. According to the European Centre for Disease Prevention and Control, 36% of Klebsiella pneumoniae isolates in EU hospitals are resistant to third-generation cephalosporins, and 18% of invasive Staphylococcus aureus infections are methicillin-resistant, underscoring the urgency of targeted testing. This resistance landscape renders syndromic treatment increasingly ineffective and dangerous. In response, the European Commission’s 2022 Action Plan on Antimicrobial Resistance mandates that all member states implement antimicrobial stewardship programs requiring diagnostics before initiating broad-spectrum antibiotics. As per Sweden’s Public Health Agency, hospitals using rapid molecular panels for bloodstream infections reduced inappropriate antibiotic use and shortened hospital stays, demonstrating the clinical value of rapid diagnostics. Similarly, the Netherlands’ National Institute for Public Health reports that carbapenemase detection kits significantly reduced carbapenem consumption in intensive care units. These outcomes validate diagnostics as therapeutic enablers. With the European Medicines Agency now requiring companion diagnostics for new anti-infectives, the clinical and regulatory imperative for precise pathogen identification continues to strengthen, solidifying diagnostics as central to resistance containment.

MARKET RESTRAINTS

Fragmented Reimbursement Policies Across Member States Limit Diagnostic Access

Despite an EU-level strategy, significant disparities in national reimbursement frameworks constrain equitable access to advanced infectious disease diagnostics, which is impeding the regional market growth. According to the European Observatory on Health Systems and Policies, only a minority of EU countries provide universal reimbursement for multiplex molecular panels, with others requiring case-by-case approval or restricting use to tertiary hospitals. In Poland, for example, rapid molecular testing for sepsis is reimbursed only in university hospitals, excluding a large share of public facilities as per the National Health Fund. Similarly, Italy’s regional health authorities apply divergent criteria, with Lombardy covering full panel testing while Sicily limits reimbursement to single-pathogen assays. This fragmentation creates diagnostic deserts where clinicians rely on slower culture methods, increasing empirical prescribing, and delaying isolation protocols. The consequence is measurable. A 2023 study published by the European Society of Clinical Microbiology and Infectious Diseases found that patients in low reimbursement regions experienced a longer time to targeted therapy compared to high reimbursement countries. Until a harmonized diagnostic payment model is adopted under the European Health Union, disparities will persist, undermining both individual outcomes and collective outbreak response effectiveness.

Lengthy Regulatory Approval Timelines Delay Innovation Adoption

The European Union’s transition from the In-Vitro Diagnostic Medical Devices Directive to the In-Vitro Diagnostic Regulation has introduced more rigorous clinical evidence and post market surveillance requirements, leading to prolonged approval timelines for novel infectious disease tests, which is further hindering the European influenza disease diagnostics market growth. According to the European Commission, the average time to obtain CE marking under IVDR exceeds one year, significantly longer than under the previous framework. This delay is particularly critical for emerging threats. During the 2023 mpox outbreak, several EU countries had to rely on emergency use authorizations for new PCR assays because formal IVDR certification was not yet granted. As per the European Diagnostics Manufacturers Association, only a minority of novel infectious disease tests submitted in 2022 received approval within one year, reflecting capacity constraints among notified bodies. Small and medium enterprises are disproportionately affected, lacking resources for complex technical documentation. Consequently, innovation is stifled at the precise moment when agility is most needed. While the regulation enhances safety, the current implementation pace risks compromising Europe’s diagnostic responsiveness during future health emergencies.

MARKET OPPORTUNITIES

Integration of Diagnostics into Primary Care Enables Early Intervention

The strategic deployment of rapid infectious disease testing in community and primary care settings is unlocking earlier treatment, isolation, and reduced transmission across Europe, which is a potential opportunity in the European market. According to the Organisation for Economic Co-operation and Development, primary care accounts for the majority of first patient contacts for respiratory and febrile illness, making this the optimal point for diagnostic triage. Countries are acting accordingly. In 2023, the United Kingdom’s National Health Service rolled out C-reactive protein and influenza RSV rapid tests to over 6 000 general practices, enabling same-day differentiation of viral versus bacterial infections. As per the Dutch College of General Practitioners, national programs providing multiplex gastrointestinal panels have reduced unnecessary antibiotic prescribing in primary care, which is demonstrating the value of rapid testing. Digital integration amplifies impact. Sweden’s primary care clinics now link rapid test results directly to the national infectious disease registry, enabling real-time outbreak detection. These decentralized models not only improve individual outcomes but also generate population-level surveillance data, transforming primary care into an active node in Europe’s early warning system.

Expansion of Pathogen Genomic Surveillance Creates Demand for Sequencing Diagnostics

Europe’s investment in large-scale pathogen genomics is driving the adoption of next-generation sequencing-based diagnostics for outbreak tracking, antimicrobial resistance profiling, and variant characterization, which is another prominent opportunity in the regional market. According to the European Centre for Disease Prevention and Control, hundreds of thousands of pathogen genomes were uploaded to EU surveillance platforms in 2023, further reflecting the rapid expansion of genomic capacity across member states. This infrastructure requires standardized sequencing workflows and bioinformatics pipelines. In response, Germany’s National Public Health Institute established 16 sequencing hubs equipped with Illumina and Oxford Nanopore platforms capable of whole genome analysis within 48 hours. France’s Pasteur Institute launched a mobile sequencing unit in 2024 to support real-time outbreak investigation in remote regions. These capabilities are no longer confined to research. Hospitals in Denmark and Finland now use sequencing to guide therapy for multidrug-resistant tuberculosis and invasive fungal infections. As genomic data becomes integral to clinical and public health decision-making, sequencing-based diagnostics are transitioning from niche to essential, opening a high-value growth frontier in infectious disease testing.

MARKET CHALLENGES

Data Interoperability Gaps Hinder Diagnostic Integration into Health Systems

Despite advances in test technology, the inability to seamlessly integrate diagnostic results into electronic health records and public health databases limits clinical utility and surveillance effectiveness across Europe, which is challenging the growth of the European influenza disease diagnostics market. According to the European Commission, only a portion of EU member states have fully interoperable systems capable of automatically transmitting laboratory results to clinicians and national disease registries, highlighting persistent fragmentation. In Spain, for example, rapid test results from primary care must be manually entered into regional surveillance platforms, causing delays of up to 72 hours as reported by the Carlos III Health Institute. Similarly, in Italy, fragmented regional health information systems prevent real-time aggregation of antimicrobial resistance data, impeding national stewardship efforts. These silos reduce the value of even the most accurate diagnostics. As per the European Health Data Space Task Force, a significant share of diagnostic data generated in outpatient settings does not reach public health authorities, limiting surveillance completeness. Until common data standards, FHIR compliance, and secure API frameworks are universally adopted, diagnostic insights will remain trapped in isolated systems, undermining both individual care coordination and population-level response capacity.

Workforce Shortages in Clinical Microbiology Impede Test Utilization and Interpretation

A critical but often overlooked bottleneck in Europe’s infectious disease diagnostics ecosystem is the shortage of trained laboratory professionals capable of operating advanced platforms and interpreting complex results, which is further challenging the regional market expansion. According to the European Society of Clinical Microbiology and Infectious Diseases, many EU countries face substantial shortages of clinical microbiologists, with vacancy rates particularly high in parts of Southern and Eastern Europe, creating operational strain. The gap is wider in rural areas where laboratories struggle to retain staff. This scarcity has direct consequences. As per the National Centre of Infectious and Parasitic Diseases, only a minority of hospitals in Bulgaria offer molecular testing for sepsis due to limited qualified personnel, restricting access to rapid diagnostics. Even where technology exists, underutilization is common. A 2023 survey in Poland found that 60% of installed multiplex panels were used below 30% of capacity due to staff unfamiliarity. The European Centre for Disease Prevention and Control warns that without targeted training programs and career incentives, this workforce gap will worsen, rendering even the most advanced diagnostics ineffective. Technology alone cannot compensate for human expertise, and without investment in laboratory education, Europe’s diagnostic potential will remain unrealized.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Insights

The reagents segment occupied the major share of 47.4% of the European market in 2024 due to their recurring demand, high test volumes, and their essential role in all diagnostic workflows. Reagents are consumed with every diagnostic test, making them indispensable across hospital laboratories, public‑health networks, and point‑of‑care sites. According to the European Centre for Disease Prevention and Control, more than 120 million infectious disease tests are performed annually in the EU for notifiable pathogens such as influenza, respiratory syncytial virus, and sexually transmitted infections. National screening programs further amplify volume. As per France’s National Public Health Agency, over 4.2 million HIV and hepatitis C tests were conducted in 2023 under universal screening mandates. According to the Robert Koch Institute, Germany’s statutory health insurance covers annual chlamydia screening for women under 25, generating more than 2 million tests each year. These institutionalized testing protocols create predictable, recurring reagent demand independent of capital‑equipment cycles. Even during non‑outbreak periods, surveillance systems require continuous reagent supply for foodborne‑pathogen monitoring, antimicrobial‑resistance tracking, and blood‑donor screening. Reagent demand is expected to remain strong over the forecast period as Europe expands surveillance capacity and routine screening programs.

The software segment is growing rapidly and is expected to register a CAGR of 12.2% over the forecast period, owing to the digital‑health integration, data analytics, and laboratory automation. European health policy increasingly mandates digital connectivity between diagnostic devices and national health‑information infrastructures. As per the European Commission’s European Health Data Space Regulation, all new diagnostic instruments placed on the market from 2025 must support secure data transmission to electronic health records and public‑health registries. This requirement has acceleratedthe adoption of laboratory‑information systems and instrument‑middleware software. According to the Danish Health Authority, more than 95% of hospital laboratories in Denmark now use integrated diagnostic software that automatically uploads results to the national Sundhed platform, enabling real‑time outbreak detection. As per the Robert Koch Institute, Germany’s electronic reporting system for notifiable diseases has reduced manual‑entry errors by 70% due to standardized digital data formats. These regulatory imperatives transform software from an optional accessory into a compliance necessity. Software adoption is expected to grow rapidly over the forecast period as EU‑wide digital‑health infrastructure becomes fully interoperable.

By Application Insights

The HIV diagnostics segment commanded for 20.5% of the regional market share in 2024. The growth of the HIV diagnostics segment in the European market is attributed to its universal testing mandates, robust screening infrastructure, and lifelong monitoring requirements. Europe maintains one of the world’s most comprehensive HIV‑testing frameworks, with all 27 EU member states implementing national guidelines recommending routine screening in primary care, emergency departments, and prenatal settings. According to the European Centre for Disease Prevention and Control, more than 5.8 million HIV tests were conducted in the EU in 2023, with 15% performed in community settings such as outreach centers and self‑testing programs. As per France’s National Public Health Agency, opt‑out HIV testing in hospitals increased diagnosis rates by 22% between 2020 and 2023. The United Kingdom’s National Health Service also distributes free rapid HIV tests through pharmacies and sexual‑health clinics, with more than 1.2 million tests provided in 2023. These structural testing mechanisms ensure consistent, high‑volume demand for both initial screening and confirmatory assays. HIV diagnostics are expected to maintain their leading position over the forecast period as EU countries strengthen early‑detection and prevention strategies.

The HPV diagnostics segment is the fastest-growing application segment and is anticipated to showcase a CAGR of 11.4% over the forecast period. The transition from cytology to primary HPV screening in national cervical‑cancer programs is primarily driving the growth of the HPV diagnostics segment in the regional market. European countries are systematically replacing Pap smears with HPV DNA testing as the primary screening method due to its superior sensitivity and longer recommended screening intervals. According to the European Commission’s 2023 Beating Cancer Plan, 21 EU member states have updated national guidelines to adopt primary HPV testing. As per the Netherlands’ National Institute for Public Health, the country screens approximately 1.2 million women annually using HPV DNA tests following full transition in 2023. France began nationwide rollout in 2024, targeting 4.5 million women with high‑risk HPV genotyping to stratify risk for CIN2+ lesions. This shift significantly increases test volume and complexity. While cytology required subjective interpretation, HPV testing uses standardized molecular platforms that enable automation and centralization. The European Cervical Cancer Prevention Network estimates that annual HPV test volume will rise from 8 million to more than 22 million by 2027, making it the fastest-expanding diagnostic application in women’s health. HPV diagnostics are expected to grow rapidly over the forecast period as more EU countries complete the transition to molecular cervical‑cancer screening.

By Technology Insights

The PCR segment dominated the market and held 50.9% of the European influenza disease diagnostics market share in 2024. The growth of the PCR segment in this regional market is driven by its gold‑standard status in sensitivity, specificity, and regulatory acceptance across infectious‑disease testing. PCR is the reference method for diagnosing a wide spectrum of infections, including HIV, hepatitis, tuberculosis, and emerging viruses. According to the European Medicines Agency, the majority of CE‑marked molecular infectious‑disease assays rely on PCR or real‑time PCR variants, reflecting well‑established performance criteria. National reference laboratories depend on PCR for confirmatory testing. As per the Robert Koch Institute’s technical guidance, PCR demonstrates sensitivity above 95% for smear‑positive tuberculosis cases. The European Centre for Disease Prevention and Control also recommends PCR for all notifiable viral hemorrhagic fevers, including Ebola and Crimean‑Congo hemorrhagic fever. This regulatory and clinical validation ensures PCR remains the first choice for high‑stakes diagnostics where false negatives carry severe consequences. Hospitals and public‑health labs prioritize PCR not only for accuracy but also for legal defensibility in outbreak investigations and blood‑safety testing. PCR is expected to maintain its dominant position over the forecast period as molecular‑testing standards and regulatory frameworks continue to emphasize high‑accuracy diagnostics.

The DNA sequencing segment is the fastest-growing technology segment and is estimated to expand at a CAGR of 12.44% over the forecast period due to its role in pathogen genomics, antimicrobial‑resistance profiling, and outbreak investigation. The European Union’s investment in pathogen genomics has institutionalized sequencing as a core public‑health function. According to the European Centre for Disease Prevention and Control, the EU Pathogen Genomic Initiative aims to sequence all invasive bacterial isolates and key viral pathogens by 2025. In 2023, hundreds of thousands of pathogen genomes were uploaded to the EU’s secure data platform, reflecting the rapid scaling of genomic surveillance. National reference laboratories are expanding capacity: France’s Pasteur Institute operates multiple high‑throughput sequencing systems for real‑time outbreak analysis, while Germany’s Robert Koch Institute coordinates a national sequencing network capable of whole‑genome analysis within 48 hours. Hospitals are also adopting sequencing for clinical decision‑making. As per Denmark’s Statens Serum Institut, sequencing‑guided therapy for multidrug‑resistant infections shows high concordance with phenotypic resistance testing. DNA sequencing is expected to grow rapidly over the forecast period as genomic surveillance becomes fully embedded in EU infectious‑disease control strategies.

By End User Insights

The laboratories segment dominated the market and accounted for 60.4% of the regional market share in 2024. The dominance of the laboratories segment in the regional market is driven by the centralized testing mandates, high‑throughput capacity, and its role in public‑health surveillance. Europe’s infectious‑disease diagnostics rely on a tiered laboratory system in which national and regional public‑health labs perform most confirmatory and surveillance testing. According to the European Centre for Disease Prevention and Control, more than 1,200 laboratories across 30 countries participate in EU pathogen‑genomics and antimicrobial‑resistance surveillance networks. These facilities process millions of samples annually for notifiable diseases, AMR monitoring, and blood‑safety screening. France’s National Reference Centre for HIV tests hundreds of thousands of samples each year, while Germany’s Robert Koch Institute oversees a network responsible for diagnostics of high‑risk pathogens such as Ebola and Lassa fever. The EU’s Joint Procurement Agreement channels bulk diagnostic purchases through these centralized labs, ensuring standardization and cost efficiency. Laboratories are expected to retain their dominant position over the forecast period as EU surveillance systems expand and high‑complexity molecular testing increases.

The hospitals segment is the fastest-growing end‑user segment and is predicted to record a CAGR of 10.05% over the forecast period due to point‑of‑care testing adoption, antimicrobial‑stewardship programs, and sepsis protocols. Hospitals increasingly deploy rapid molecular diagnostics at the bedside to guide immediate therapy for life‑threatening infections. According to the European Society of Intensive Care Medicine, sepsis protocols in a majority of EU university hospitals now include multiplex PCR panels for bloodstream infections, delivering actionable results in under an hour. As per a clinical audit from Karolinska University Hospital, rapid diagnostics reduced time to targeted antibiotics by more than six hours and lowered mortality. Antimicrobial‑stewardship teams also use rapid respiratory and gastrointestinal panels to de‑escalate unnecessary antibiotics. The Netherlands’ National Institute for Public Health reports that such panels reduced broad‑spectrum antibiotic use by 30% in participating hospitals. These clinical outcomes justify investment in on‑site diagnostics, transforming hospitals from sample‑collection points into active diagnostic centers.

COUNTRY-LEVEL ANALYSIS

Germany Infectious Disease Diagnostics Market Analysis

Germany held the leading position in the Europe infectious disease diagnostics market in 2024 with a 20.4% share. The lead in this regional market is due to its advanced public‑health infrastructure, extensive hospital network, and strong diagnostic‑innovation ecosystem. The Robert Koch Institute coordinates a nationwide surveillance system that includes multiple reference laboratories responsible for confirmatory testing of notifiable diseases. According to the Federal Statistical Office, millions of infectious disease tests are conducted annually across HIV, hepatitis, and sexually transmitted infections, reflecting high screening coverage. Germany’s statutory health‑insurance system reimburses molecular diagnostics for sepsis, respiratory infections, and gastrointestinal pathogens, ensuring broad adoption. The country also maintains one of Europe’s most comprehensive antimicrobial‑resistance monitoring programs, supported by routine sequencing of invasive bacterial isolates. With major diagnostic manufacturers headquartered domestically, Germany benefits from rapid technology transfer and strong clinical‑validation capacity. These combined strengths in surveillance, reimbursement, and innovation reinforce Germany’s position as Europe’s diagnostic powerhouse for the years ahead.

United Kingdom Infectious Disease Diagnostics Market Analysis

The United Kingdom captured a promising share of the European infectious‑disease diagnostics market in 2024. The centralized National Health Service and proactive screening policies are fuelling the growth of the UK influenza disease diagnostics market. Public‑health agencies conduct extensive testing for HIV, hepatitis, and sexually transmitted infections, supported by opt‑out screening in emergency and prenatal settings. The NHS continues to expand rapid molecular testing for sepsis and respiratory pathogens across hospitals as part of national antimicrobial‑resistance initiatives. According to NHS Digital, point‑of‑care testing remains widely distributed through pharmacies and sexual‑health clinics, supporting early detection. The UK Health Security Agency leads in pathogen genomics, with large‑scale sequencing capacity now applied to tuberculosis and antimicrobial‑resistance surveillance. Despite regulatory divergence after Brexit, the UK maintains alignment with EU diagnostic standards, ensuring continued access to certified technologies. With its strong genomic infrastructure and digital‑health integration, the UK is positioned to remain a high‑impact market.

France Infectious Disease Diagnostics Market Analysis

France is anticipated to register a prominent CAGR in the Europe infectious disease diagnostics market over the forecast period due to its universal testing mandates, strong public‑health institutions, and a well‑established reference‑laboratory network. The National Public Health Agency oversees systematic screening programs for HIV, hepatitis, and chlamydia, contributing to high annual testing volumes. France has implemented opt‑out HIV testing in hospitals, improving early diagnosis rates. The country is transitioning to primary HPV testing for cervical‑cancer screening, targeting millions of women annually. The Pasteur Institute plays a central role in pathogen genomics, supporting outbreak investigation and antimicrobial‑resistance tracking. France’s Social Security system provides full reimbursement for infectious‑disease diagnostics, including advanced molecular panels, ensuring equitable access nationwide. With its combination of policy‑driven testing and scientific leadership, France is expected to remain a high‑volume and influential diagnostics market.

Italy Infectious Disease Diagnostics Market Analysis

Italy is expected to account for a notable share of the Europe infectious disease diagnostics market over the forecast period owing to its infectious‑disease burden, regional disparities, and ongoing laboratory modernization. National health data indicate persistent challenges related to tuberculosis and hepatitis C, prompting regional authorities to expand diagnostic capacity. Investments in multiplex PCR systems for sepsis and respiratory infections continue across major hospital networks. Italy participates in European genomic‑surveillance initiatives, with national institutions sequencing antimicrobial‑resistant pathogens from all regions. While southern areas face infrastructure gaps, northern and central regions lead in rapid‑test adoption and molecular‑diagnostic deployment. The Ministry of Health’s National Plan for Antimicrobial Resistance mandates diagnostic stewardship in hospitals, creating structured demand for advanced testing. With rising investment and strong public‑health needs, Italy is positioned for continued growth in diagnostic capability.

Netherlands Infectious Disease Diagnostics Market Analysis

The Netherlands is projected to grow at a healthy CAGR in the Europe infectious disease diagnostics market during the forecast period. The integrated diagnostic ecosystem, strong antimicrobial‑stewardship programs, and early adoption of genomic surveillance are driving the influenza disease diagnostics market growth in the Netherlands. The National Institute for Public Health and the Environment oversees a centralized laboratory network that performs extensive infectious‑disease testing, including population‑level chlamydia screening. The Netherlands pioneered the use of rapid molecular panels in primary care, contributing to reduced antibiotic prescribing. Leading academic centers apply whole‑genome sequencing to guide treatment of multidrug‑resistant infections, reinforcing the country’s scientific leadership. National digital‑health strategies mandate real‑time transmission of diagnostic results to centralized registries, improving outbreak detection and public‑health response. With its combination of clinical integration, technological advancement, and digital connectivity, the Netherlands is expected to remain a model for scalable diagnostic excellence in Europe.

COMPETITIVE LANDSCAPE

multinational diagnostics giants, specialized European innovators, and public health-aligned technology providers operating under one of the world’s most stringent regulatory regimes. The market is highly innovation-driven yet tightly governed by the In Vitro Diagnostic Regulation, which demands rigorous clinical evidence and post-market surveillance. Leading participants compete not on price but on analytical performance, speed of result turnaround, regulatory dossiers, and integration into national health information systems. Differentiation occurs through platform versatility, with companies offering syndromic panels that cover multiple pathogens in a single test and through seamless connectivity to electronic health records and public health registries. Smaller firms often focus on niche applications such as antimicrobial resistance genotyping or tropical disease diagnostics while leveraging partnerships with reference laboratories. The convergence of clinical need, public health mandate, and digital health infrastructure makes regulatory agility, scientific validation, and health system integration the decisive competitive advantages in this mission-critical market.

KEY MARKET PLAYERS

The leading companies operating in the Europe infectious disease diagnostics market include:

• Abbott Laboratories
• bioMérieux SA
• Hologic, Inc.
• Danaher Corporation
• Becton, Dickinson and Company
• Cepheid, Inc.
• Thermo Fisher Scientific Inc.
• Roche Diagnostics
• Alere Inc.
• DiaSorin S.p.A.
• Quidel Corporation
• Bio-Rad Laboratories, Inc.

TOP PLAYERS IN THE MARKET

• Roche Diagnostics is a pivotal force in the Europe Infectious Disease Diagnostics Market, offering a comprehensive portfolio of molecular and serological tests for HIV, hepatitis, tuberculosis, and emerging pathogens. The company’s Cobas platforms are widely deployed across hospital and reference laboratories for high-throughput viral load monitoring and blood screening. In 2024, Roche received CE marking for a new multiplex respiratory panel detecting influenza, RSV, and SARS-CoV-2 variants with enhanced sensitivity for immunocompromised patients. The firm also expanded its antimicrobial resistance testing menu on the Cobas Infinity system, enabling real-time resistance profiling in sepsis cases. Globally, Roche supplies diagnostic solutions to over 150 countries and collaborates with the World Health Organization on HIV and hepatitis elimination programs, reinforcing its role as a cornerstone of international infectious disease control.
• Abbott Laboratories maintains a strong presence in Europe through its rapid point-of-care and molecular diagnostics for HIV, hepatitis, and sexually transmitted infections. The company’s Alinity m and ID NOW platforms are used in hospitals, clinics, and community settings for same-day diagnosis of chlamydia, gonorrhea, and influenza. In 2023, Abbott launched a next-generation HIV viral load assay with a lower detection limit of 20 copies per milliliter, meeting stringent European treatment monitoring guidelines. It also enhanced its mPLEX respiratory panel to include human metapneumovirus and adenovirus in response to post pandemic surveillance needs. Abbott’s global access programs deliver affordable HIV and hepatitis tests to low-resource regions while its European manufacturing facilities in Ireland and Germany ensure supply chain resilience and regulatory compliance across the continent.
• bioMérieux is a European leader in infectious disease diagnostics, specializing in syndromic testing, antimicrobial resistance detection, and blood culture systems. The company’s BioFire FilmArray platforms dominate hospital molecular testing for meningitis, gastroenteritis, and pneumonia across Western Europe. In early 2024, bioMérieux introduced a new gastrointestinal panel that detects 26 pathogens, including emerging norovirus variants and Shiga toxin producing E coli, with a 45-minute turnaround time. The firm also expanded its VITEK MS microbial identification system with a curated database for tropical pathogens supporting travel medicine clinics in Germany and the Netherlands. Headquartered in France, bioMérieux collaborates closely with the European Centre for Disease Prevention and Control on outbreak response and supplies diagnostic solutions to over 160 countries, making it a key enabler of global pathogen surveillance and clinical microbiology.

TOP STRATEGIES USED BY THE KEY MARKET PARTICIPANTS

Key players in the Europe Infectious Disease Diagnostics Market focus on regulatory compliance under the In Vitro Diagnostic Regulation, strategic alignment with national public health programs, development of multiplex and point of care testing platforms, integration of artificial intelligence for result interpretation, and expansion of pathogen genomic and antimicrobial resistance testing portfolios to meet evolving clinical and surveillance needs across diverse European healthcare systems.

MARKET SEGMENTATION

This Europe infectious disease diagnostics market research report is segmented and sub-segmented into the following categories.

By Product

• Instruments
• Reagents
• Services
• Software

By Application

• Hepatitis B
• Hepatitis C
• Human Immunodeficiency Virus (HIV)
• Tuberculosis (TB)
• Chlamydia trachomatis
• Neisseria gonorrhoeae (CT/NG)
• Human papillomavirus (HPV)
• Methicillin-resistant Staphylococcus aureus (MRSA)
• Others (Influenza, Ebola, Typhoid, Malaria, and Dengue)

By Technology

• PCR
• INAAT
• DNA Sequencing
• Hybridization

By End User

• Hospital
• Laboratories

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe